Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Francisco Rocha-Gonçalves"'
Autor:
Francisco Rocha Gonçalves
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 75-78 (2022)
Externí odkaz:
https://doaj.org/article/00cee6b1b079475793301e00a38bdd4e
Autor:
Joaquim A. Meireles-Brandão, Lúcia R. Meireles-Brandão, Rui Coelho, Francisco Rocha-Gonçalves
Publikováno v:
Revista Portuguesa de Cardiologia, Vol 41, Iss 8, Pp 681-688 (2022)
Introduction and Objectives: Lifestyle changes are frequently insufficient to reduce cardiovascular (CV) risk in patients with dyslipidemia. This study aims to characterize the long-term evolution of lipid profile and CV risk of patients under primar
Externí odkaz:
https://doaj.org/article/d70c89f840934b9ead9293b7b2f30ed0
Autor:
Cristina Gavina, Inês Falcão-Pires, João Santos-Faria, Benjamim Marinho, Jorge Almeida, João Rodrigues, Paulo Pinho, Francisco Rocha-Gonçalves, Adelino Leite-Moreira
Publikováno v:
Revista Portuguesa de Cardiologia, Vol 41, Iss 1, Pp 3-14 (2022)
Introduction and objectives: Among patients with aortic stenosis (AS), interstitial fibrosis has been associated with progression to heart failure and is a marker of poorer prognosis. We aimed to assess the impact of myocardial fibrosis on clinical e
Externí odkaz:
https://doaj.org/article/0f34a7f648134ffe816fd0bd86e219a0
Autor:
Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu de Sousa, Deolinda Sousa Pereira, Marina Borges
Publikováno v:
Health Economics Review, Vol 11, Iss 1, Pp 1-13 (2021)
Highlights i. The results obtained in the AC-DHP cohort, which included Pertuzumab as a NeoT, suggest better clinical outcomes compared to the AC-DH group, a confirmation based on real-world data. ii. Some patient profiles seem to be more promising c
Externí odkaz:
https://doaj.org/article/c09cb8f7d2b142abb81bf3f39656212d
Autor:
Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R. Penrod, John C. O’Donnell, Maria José Bento, Francisco Rocha Gonçalves
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background As part of the multinational I-O Optimise research initiative, this retrospective cohort study of patients with advanced non-small cell lung cancer (NSCLC) evaluated real-world treatment patterns and survival prior to immunotherap
Externí odkaz:
https://doaj.org/article/5d40a56e303547fa8facc7b7bfdb2db5
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 65-68 (2020)
At present, for patients with metastatic and castration-resistant prostate cancer, European Society for Medical Oncology and National Comprehensive Cancer Network guidelines recommend enzalutamide (E) or abiraterone (A). There are still a few studies
Externí odkaz:
https://doaj.org/article/d6d72225cd664d78a35b187df3811ab7
Autor:
Francisco Rocha-Gonçalves
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 81-85 (2020)
Externí odkaz:
https://doaj.org/article/c6e79caf9b23425eb014a98ac8469a57
Publikováno v:
Revista Portuguesa de Cardiologia, Vol 38, Iss 12, Pp 883-895 (2019)
Resumo: Nos anos 1980 assistiu‐se a uma evolução profunda do conhecimento sobre a fisiopatologia da insuficiência cardíaca (IC): outrora considerada uma síndrome clínica de origem fundamentalmente estrutural, a IC começou a ser vista como a
Externí odkaz:
https://doaj.org/article/f4e3bb1e4efa491a9db070164a2598cb
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 69-71 (2020)
Therapeutic drug monitoring (TDM) has as its main objective to ensure that the plasma drug concentration remains within the appropriate range. Regarding the economic dimension of TDM, it is known that there are gains in health outcomes; however, ther
Externí odkaz:
https://doaj.org/article/441e6d880ce545548dd19e48f9ac77c3
Autor:
Joaquim A. Meireles Brandão, Lúcia R. Meireles-Brandão, Rui Coelho, Francisco Rocha-Gonçalves
Publikováno v:
Revista Portuguesa de Cardiologia, Vol 38, Iss 7, Pp 485-493 (2019)
Introduction and Objective: Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk factor but is closely associated with other similar risk factors that are manageable with appropriate treatment and guidance. We aimed to study the impact of usi
Externí odkaz:
https://doaj.org/article/5af4047b59c5424e945c972a8d957da8